- |||||||||| Trial completion, Enrollment change: Lipoic Acid as a Treatment for Acute Optic Neuritis (clinicaltrials.gov) - Apr 26, 2019
P1, N=31, Completed, N=86 --> 40 | Recruiting --> Terminated; interim anlaysis failed: palifermin does not promote thymopoeisis after alemtuzumab Recruiting --> Completed | N=54 --> 31
- |||||||||| Trial completion, Trial completion date, Trial primary completion date: Mindfulness-based Stress Reduction in Multiple Sclerosis (clinicaltrials.gov) - Mar 1, 2019
P=N/A, N=50, Completed, Phase classification: P4 --> P=N/A Recruiting --> Completed | Trial completion date: Aug 2015 --> Aug 2016 | Trial primary completion date: Aug 2015 --> Aug 2016
- |||||||||| Trial completion, Trial completion date, Trial primary completion date: SAMSPAP: Sleep Apnea in Multiple Sclerosis Positive Airway Pressure Trial (clinicaltrials.gov) - Jan 12, 2019
P=N/A, N=49, Completed, Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Mar 2019 --> Nov 2018 | Trial primary completion date: Sep 2018 --> Nov 2018
- |||||||||| Campath (alemtuzumab) / Sanofi
Trial completion date, Trial withdrawal, Trial primary completion date: Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis (clinicaltrials.gov) - Jan 8, 2019 P1/2, N=0, Withdrawn, Recruiting --> Completed | Trial completion date: Mar 2019 --> Nov 2018 | Trial primary completion date: Sep 2018 --> Nov 2018 Trial completion date: Jan 2020 --> Sep 2018 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2020 --> Aug 2018
- |||||||||| Betaseron (IFN-β-1b) / Bayer
Phase classification: Betaseron Pregnancy Registry (clinicaltrials.gov) - Dec 12, 2018 P=N/A, N=113, Completed, Trial completion date: Jan 2020 --> Sep 2018 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2020 --> Aug 2018 Phase classification: P4 --> P=N/A
- |||||||||| Enrollment change, Trial withdrawal: Stem Cell Therapy for Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Oct 25, 2018
P2, N=0, Withdrawn, Active, not recruiting --> Completed | N=100 --> 135 | Trial completion date: Feb 2018 --> Oct 2018 N=57 --> 0 | Completed --> Withdrawn
- |||||||||| Clinical data, Trial completion, Trial completion date, Trial primary completion date, Adverse events: Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions (clinicaltrials.gov) - Sep 26, 2018
P=N/A, N=3000, Completed, N=12 --> 0 | Suspended --> Withdrawn Recruiting --> Completed | Trial completion date: Mar 2018 --> Jan 2017 | Trial primary completion date: Mar 2018 --> Dec 2016
- |||||||||| Trial completion, Phase classification, Trial completion date, Trial primary completion date: SIAMMS-II: Repeat Infusion of Autologous Bone Marrow Cells in Multiple Sclerosis (clinicaltrials.gov) - Aug 23, 2018
P=N/A, N=4, Completed, Recruiting --> Completed Recruiting --> Completed | Phase classification: P1 --> PN/A | Trial completion date: Sep 2016 --> Aug 2018 | Trial primary completion date: Sep 2016 --> Sep 2017
- |||||||||| Trial completion: Power Over Pain (POP) Study (clinicaltrials.gov) - Jun 27, 2018
P=N/A, N=177, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Biomarker, Enrollment change, Trial termination: Therapeutic Imaging Biomarkers for Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Jun 6, 2018
P=N/A, N=6, Terminated, Active, not recruiting --> Completed N=17 --> 6 | Active, not recruiting --> Terminated; Principal investigator was unable to fulfill his responsibilities.
- |||||||||| Trial completion, Trial completion date, Trial primary completion date: Implementing Physical Activity Guidelines for Adults With MS (clinicaltrials.gov) - Jun 1, 2018
P=N/A, N=94, Completed, Trial completion date: Oct 2019 --> Oct 2018 Recruiting --> Completed | Trial completion date: Mar 2017 --> Mar 2018 | Trial primary completion date: Dec 2016 --> Mar 2018
- |||||||||| Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis (clinicaltrials.gov) - May 30, 2018
P1, N=2, Terminated, Recruiting --> Completed | Trial completion date: Mar 2017 --> Mar 2018 | Trial primary completion date: Dec 2016 --> Mar 2018 N=100 --> 2 | Trial completion date: Jan 2019 --> May 2018 | Recruiting --> Terminated | Trial primary completion date: Jan 2018 --> May 2018
- |||||||||| Tysabri (natalizumab) / Biogen, Royalty
Trial completion: Ireland Natalizumab (TYSABRI) Observational Program (clinicaltrials.gov) - May 4, 2018 P=N/A, N=191, Completed, N=100 --> 2 | Trial completion date: Jan 2019 --> May 2018 | Recruiting --> Terminated | Trial primary completion date: Jan 2018 --> May 2018 Active, not recruiting --> Completed
|